Dorina Bischof

  • Citations Per Year
Learn More
BACKGROUND Risks that are potentially associated with long-term therapies should be assessed. OBJECTIVE The present analyses were performed to determine the risk of malignancy in patients with multiple sclerosis (MS) receiving subcutaneous (sc) interferon (IFN) beta-1a, using pooled safety data from key clinical trials and data from the Merck Serono(More)
BACKGROUND Data are limited for mortality and comorbidities in patients with multiple sclerosis (MS). OBJECTIVES Compare mortality rates and event rates for comorbidities in MS (n=15,684) and non-MS (n=78,420) cohorts from the US Department of Defense (DoD) database. METHODS Comorbidities and all-cause mortality were assessed using the database. Causes(More)
  • 1